Michael Gunnar Knell Net Worth

The estimated Net Worth of Michael Gunnar Knell is at least $3.16 Million dollars as of 8 March 2024. Mr Knell owns over 808 units of Charles River Laboratories International stock worth over $1,359,776 and over the last 13 years he sold CRL stock worth over $1,801,919.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Knell CRL stock SEC Form 4 insiders trading

Mr has made over 8 trades of the Charles River Laboratories International stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 808 units of CRL stock worth $216,156 on 8 March 2024.

The largest trade he's ever made was selling 3,456 units of Charles River Laboratories International stock on 7 August 2020 worth over $748,570. On average, Mr trades about 345 units every 37 days since 2012. As of 8 March 2024 he still owns at least 7,024 units of Charles River Laboratories International stock.

You can see the complete history of Mr Knell stock trades at the bottom of the page.

Mr. Michael Gunnar Knell biography

Michael Gunnar Knell is the Corp. Sr. VP & Chief Accounting Officer at Charles River Laboratories International.

How old is Mr Knell?

Mr Knell is 44, he's been the Corp. Sr. VP & Chief Accounting Officer of Charles River Laboratories International since . There are 21 older and no younger executives at Charles River Laboratories International. The oldest executive at Charles River Laboratories International Inc. is Stephen Chubb, 76, who is the Independent Director.

Insiders trading at Charles River Laboratories International

Over the last 22 years, insiders at Charles River Laboratories International have traded over $220,588,205 worth of Charles River Laboratories International stock and bought 18,392 units worth $3,841,397 . The most active insiders traders include James C Foster, Richard F Wallman, and David P Johst. On average, Charles River Laboratories International executives and independent directors trade stock every 14 days with the average trade being worth of $2,223,188. The most recent stock trade was executed by Joseph W La Plume on 8 August 2024, trading 1,780 units of CRL stock currently worth $354,861.

What does Charles River Laboratories International do?

charles river provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. #drugdiscovery #biotech #biotechnology #pharmaceuticals #cro

Complete history of Mr Knell stock trades at Bruker Corp and Charles River Laboratories International

Charles River Laboratories International executives and stock owners

Charles River Laboratories International executives and other stock owners filed with the SEC include:

• James Foster,
  Chairman of the Board, President, Chief Executive Officer
• David Smith,
  Chief Financial Officer, Corporate Executive Vice President
• James C. Foster,
  Chairman, CEO & Pres
• Joseph LaPlume,
  Corporate Executive Vice President, Corporate Development and Strategy
• Birgit Girshick,
  Corporate Executive Vice President, Global Discovery and Safety Assessment, Biologics and Avian
• William Barbo,
  Corporate Executive Vice President and Chief Commercial Officer
• David Ross Smith,
  Corp. Exec. VP & CFO
• William D. Barbo,
  Chief Commercial Officer & Corp. Exec. VP
• Joseph W. LaPlume,
  Corp. Exec. VP of Corp. Devel. & Strategy
• Birgit Girshick,
  Corp. Exec. VP & COO
• George Milne,
  Lead Independent Director
• George Massaro,
  Independent Director
• Robert Bertolini,
  Independent Director
• Richard Reese,
  Independent Director
• Richard Wallman,
  Independent Director
• Martin Mackay,
  Independent Director
• Deborah Kochevar,
  Independent Director
• Jean-Paul Mangeolle,
  Independent Director
• Stephen Chubb,
  Independent Director
• Virginia Wilson,
  Independent Director
• Nancy Andrews,
  Independent Director
• George Llado,
  Director
• Matthew L. Daniel,
  Corp. Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Todd Spencer,
  Corp. VP of Investor Relations
• Mark Mintz,
  Corp. Sr. VP & Chief Information Officer
• Prof. Julie Frearson Ph.D.,
  Corp. Sr. VP & Chief Scientific Officer
• Michael Gunnar Knell,
  Corp. Sr. VP & Chief Accounting Officer
• John J Crowley,
  SVP, Chief Accounting Officer
• Davide Molho,
  Corporate Executive VP
• Michael Gunnar Knell,
  CSVP&Chief Accounting Officer
• Craig B. Thompson,
  Director
• John W Kuo,
  CEVP General Counsel & CCO
• Victoria L Creamer,
  EVP & Chief People Officer
• David P Johst,
  Corporate Executive VP
• Jorg Geller,
  OFFICERS
• Nancy Gillett,
  Vice President
• Thomas F Ackerman,
  Sr. Vp and CFO
• Samuel O Md Thier,
  Director
• William Waltrip,
  Director
• Nancy T Chang,
  Director
• Christopher Berthoux,
  OFFICERS
• Douglas E Rogers,
  Director
• Real H Renaud,
  Executive Vice President
• Brian Bathgate,
  Corporate Vice President
• Joanne P Acford,
  Corp. Sr VP, GC and Corp. Sec
• David J Elliott,
  Officer
• Linda Mc Goldrick,
  Director
• Stephanie B Wells,
  Senior Vice President
• Cheri L Walker,
  Corporate Senior VP
• Nicholas Ventresca,
  Senior Vice President
• Michael F Ankcorn,
  Corporate Sr. Vice President
• Walter S Nimmo,
  Director
• S Louise Mccrary,
  Director
• John C Ho,
  Senior Vice President
• Alastair Stuart Mcewan,
  Corporate Vice President
• John Urquhart,
  Director
• Dennis R Shaughnessy,
  Sr. VP Corporate Development
• Robert Cawthorn,
  Director
• Flavia Pease,
  Corporate Executive VP & CFO
• Shannon M Parisotto,
  CEVP, Disc & Safety Assessment
• Reshema Kemps Polanco,
  Director